Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental designs for phase I and phase I/II dose-finding studies.

J O'Quigley1, S Zohar

  • 1Institut Curie, Paris, France.

British Journal of Cancer
|January 26, 2006
PubMed
Summary

Standard "memoryless" dose-finding study designs in early clinical trials are inefficient. Newer "memory" designs require fewer patients and better identify the maximum tolerated dose (MTD).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced charge density wave coherence in a light-quenched, high-temperature superconductor.

Science (New York, N.Y.)·2022
Same author

dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.

Computer methods and programs in biomedicine·2018
Same author

Rapid in situ X-ray position stabilization via extremum seeking feedback.

Journal of synchrotron radiation·2016
Same author

A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.

Methods of information in medicine·2015
Same author

Designs of drug-combination phase I trials in oncology: a systematic review of the literature.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Competing designs for drug combination in phase I dose-finding clinical trials.

Statistics in medicine·2014

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacology

Background:

  • The statistical design of early-phase dose-finding studies is critical for drug development.
  • Current standard designs often fail to meet the primary objectives of these trials.
  • The widely used
  • memoryless
  • design has significant limitations.

Purpose of the Study:

  • To review the rationale and objectives of dose-finding studies in phase I and phase I/II clinical trials.
  • To evaluate the shortcomings of standard
  • memoryless
  • designs.
  • To highlight the advantages of newer
  • memory
  • designs.

Main Methods:

  • Review of statistical principles in dose-finding study design.
  • Comparative analysis of
  • memoryless
  • and
  • memory
  • designs.
  • Re-analysis of published clinical trial data.

Main Results:

  • Standard
  • memoryless
  • designs are inefficient and do not meet study objectives.
  • Designs with memory demonstrate superiority over memoryless designs.
  • Memory designs require fewer patients overall and to reach the maximum tolerated dose (MTD).
  • Memory designs concentrate a higher percentage of patients at or near the MTD.

Conclusions:

  • "Memory" designs represent a significant improvement over traditional "memoryless" designs for dose-finding studies.
  • Implementing memory designs can lead to more efficient and effective early-phase clinical trials.
  • Better patient allocation and MTD identification are key benefits of memory designs.

Related Experiment Videos